Stockscreener 앱 받기
16.11
24.91%
-5.345
시간 외 거래:
16.20
0.085
+0.53%
전일 마감가:
$21.46
열려 있는:
$16.02
하루 거래량:
18.08M
Relative Volume:
5.66
시가총액:
$12.51B
수익:
$220.00K
순이익/손실:
$-1.08B
주가수익비율:
-11.15
EPS:
-1.4448
순현금흐름:
$-326.53M
1주 성능:
-27.02%
1개월 성능:
-14.83%
6개월 성능:
-14.78%
1년 성능:
-34.68%
1일 변동 폭
$15.14
$16.81
1주일 범위
$15.14
$22.55
52주 변동 폭
$13.83
$30.98
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
305-203-2034
주소
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
16.11 | 16.65B | 220.00K | -1.08B | -326.53M | -1.4448 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 108.71B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 74.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.61B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 41.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.81B | 5.36B | 287.73M | 924.18M | 2.5229 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-08 | 개시 | Stifel | Buy |
| 2026-03-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-17 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-17 | 개시 | Barclays | Underweight |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Neutral |
| 2025-07-01 | 개시 | UBS | Buy |
| 2025-06-11 | 개시 | Leerink Partners | Underperform |
| 2025-03-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 개시 | Evercore ISI | Outperform |
| 2025-02-28 | 개시 | Goldman | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-05-07 | 개시 | Citigroup | Buy |
| 2024-03-26 | 개시 | Stifel | Buy |
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Summit Therapeutics Shock Move Hits Nasdaq Futures - Kalkine Media
SMMT Stock Plunges On Wider Q1 Loss, Lung Cancer Clinical Trial Update - Stocktwits
Merck's Biggest Looming Rival In Cancer Just Took A Gut Punch - Investor's Business Daily
U.S. Markets Closed Mixed Friday As Pershing Square Led, Summit Therapeutics Lagged - Barron's
Summit Therapeutics Shares Fall After 1Q Loss Widens - Moomoo
Summit Therapeutics Stock Plunges 23%: The Ivonescimab Update Shaking Its Keytruda Challenge - TechStock²
SMMT Maintains by Piper Sandler -- Price Target Lowered to $16.00 - GuruFocus
Summit Therapeutics (SMMT) Shares Drop 22% After Trial Update - GuruFocus
Summit Therapeutics (NASDAQ:SMMT) Shares Gap DownTime to Sell? - MarketBeat
Stock Market Today: Apple Earnings Power S&P 500, Nasdaq To Records; Trump Hits EU - Benzinga
Summit Therapeutics (SMMT) Sees Significant Drop in Stock Price - GuruFocus
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III - BioWorld News
Evercore Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Summit Therapeutics Stock Dips After Q1 Financial Report - Benzinga
Summit Therapeutics (SMMT) slides 24.7% as investors digest Q1 loss and an interim trial update that didn’t deliver an early efficacy win - Quiver Quantitative
Summit Therapeutics stock falls after Q1 update (SMMT:NASDAQ) - Seeking Alpha
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal - Yahoo Finance
Summit Therapeutics PLC $SMMT Shares Sold by Pictet Asset Management Holding SA - MarketBeat
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026 - BioSpace
Clear Street Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Cuts Target Price to $31 - Moomoo
Impressive Progress for SMMT with New Bispecific Antibody Develo - GuruFocus
Summit Therapeutics (SMMT) Reports Q1 EPS Beat with Strong Cash Position - GuruFocus
Is Summit Therapeutics (SMMT) Attractive After Q1 2026? EPS $(0. - GuruFocus
Press Release: Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026 - 富途牛牛
Summit Therapeutics (NASDAQ: SMMT) posts larger Q1 loss amid cash burn and trials - Stock Titan
Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q1 Adjusted Loss $0.15 per Share, vs. FactSet Est of $-0.17 - marketscreener.com
Summit Therapeutics PLC (Nasdaq: SMMT) recently disclosed its financial report and business development updates for the first quarter ending March 31, 2026. - Bitget
Summit Therapeutics (NASDAQ: SMMT) ramps ivonescimab trials, widens Q1 2026 net loss - Stock Titan
Summit Therapeutics: It Still Feels Like The Market Got Ahead Of Itself (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics (SMMT) Expected to Announce Earnings on Thursday - MarketBeat
Summit Therapeutics (SMMT) Leads Healthcare Stocks with 372.66% CapEx Growth - GuruFocus
Summit Therapeutics leads all large-cap healthcare stocks in YoY CapEx growth (XLV:NYSEARCA) - Seeking Alpha
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring A 40.93% Potential Upside - DirectorsTalk Interviews
SMMT stock up 24% in three months: Here's what you need to know - MSN
Summit Therapeutics shows rising price performance with jump to 82 RS rating - MSN
Trading Systems Reacting to (SMMT) Volatility - Stock Traders Daily
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
SMMT Technical Analysis | Trend, Signals & Chart Patterns | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Summit Therapeutics (NASDAQ:SMMT) Shares Down 6.2%Time to Sell? - MarketBeat
Investors Buy Large Volume of Call Options on Summit Therapeutics (NASDAQ:SMMT) - MarketBeat
SMMT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Summit Therapeutics (SMMT) jumps as investors refocus on upcoming ivonescimab data and bullish recent coverage - Quiver Quantitative
Positive Outlook for Summit Therapeutics (SMMT) Following ASCO P - GuruFocus
Summit Therapeutics (NASDAQ:SMMT) Sees Strong Trading VolumeHere's Why - MarketBeat
Stifel reiterates Summit Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Summit partner selection for ASCO ‘likely a major positive,’ says Guggenheim - TipRanks
Guggenheim Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Summit Therapeutics Inc. (SMMT): Investor Outlook on This Biotech Stock with 23.70% Potential Upside - DirectorsTalk Interviews
Board seats, pay and equity plan on ballot at Summit Therapeutics (NASDAQ: SMMT) - Stock Titan
UBS reiterates Buy on Summit Therapeutics stock ahead of trial data - Investing.com Canada
Summit Therapeutics Inc (SMMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Summit Therapeutics Inc 주식 (SMMT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
2.45%
자본화:
|
볼륨(24시간):